Talk:2011 Group Project 11
Group 11: User:z3308965 | User:z3292953 | User:z3308968 | User:z3272325 | User:z3284061
Plagiarism
--Mark Hill 07:35, 30 September 2011 (EST) Currently all students originally assigned to each group are listed as equal authors/contributors to their project. If you have not contributed the content you had originally agreed to, nor participated in the group work process, then you should contact the course coordinator immediately and either discuss your contribution or request removal from the group author list. Remember that all student online contributions are recorded by date, time and the actual contributed content. A similar email reminder will be sent to all current students.
Please note the Universities Policy regarding Plagiarism
In particular this example:
- "Claiming credit for a proportion of work contributed to a group assessment item that is greater than that actually contributed;"
Academic Misconduct carries penalties. If a student is found guilty of academic misconduct, the penalties include warnings, remedial educative action, being failed in an assignment or excluded from the University for two years.
2011 Projects: Turner Syndrome | DiGeorge Syndrome | Klinefelter's Syndrome | Huntington's Disease | Fragile X Syndrome | Tetralogy of Fallot | Angelman Syndrome | Friedreich's Ataxia | Williams-Beuren Syndrome | Duchenne Muscular Dystrolphy | Cleft Palate and Lip
Hi Guys, I have started working on pathophysiology and modified some of the headings to include ones that were more relevant for Cleft palate and Lip.
--Tahmina Lata 21:51, 15 August 2011 (EST)
Cleft Palate
--Tahmina Lata 19:16, 15 August 2011 (EST)
So after careful consideration we have come to realise that Cleft Palate/Lip will be a more relevant topic to create a page about. Some of you guys left last week when we registered this topic with Dr Hill. Please post here if you are still unsure of the topic. At this stage we are all reseraching different things on the topic so we can discuss about it this week.
--Tahmina Lata 16:44, 15 August 2011 (EST)
There appears to be no group discussion here on possible project topics?? --Mark Hill 23:55, 7 August 2011 (EST)
We have decided to research each subheading listed on the Group Project page and then share all the information found next week. We will then be able to determine a clearer structure to the page based on what literature is available.
--Tahmina Lata 12:34, 11 August 2011 (EST)
Review Article "Cystic fibrosis: pathogenesis and future treatment strategies"-This review summarizes our current understanding of the pathophysiology and treatment of cystic fibrosis lung disease[1]
Research Article "Nasal endoscopic evaluation of children and adolescents with cystic fibrosis"-The questionnaire, clinical examination and especially nasal endoscopy performed as part of this research lead to a detailed assessment of the nasal characteristics of children and adolescents with cystic fibrosis. [2]
--Tahmina Lata 23:13, 10 August 2011 (EST)
Hi Guys,
I've modified the page with the required subheadings, we can change them later but it's important to get our heads around the foundations.
If have have anything to add, please do so. if you have any questions, post it here and we will try and help. --z3284061 22:52, 10 August 2011 (EST)
Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis.Rogers GB, Hoffman LR, Döring G. J Cyst Fibros.2011 Jul 18. [Epub ahead of print]
Vitamin D receptor agonists inhibit pro-inflammatory cytokine production from the respiratory epithelium in cystic fibrosis.McNally P, Coughlan C, Bergsson G, Doyle M, Taggart C, Adorini L, Uskokovic MR, El-Nazir B, Murphy P, Greally P, Greene CM, McElvaney NG.J Cyst Fibros. 2011 Jul 22.
--z3292953 15:59, 9 August 2011 (EST)
Hey Guys:
How are we going in the research process? Well, In case anyone wants to change the topic Tomorrow will be the last day we get to change! That’s if everyone agrees to do so.
For the time being, we are working on Cystic Fibrosis. I’ve found some interesting articles regarding the treatment. The first one is a research while the other 2 are both Reviews.
I’ve Moved the articles of z3292953 to the discussion Page :)
Looking forward to create a great wiki page. --z3284061 22:34, 10 August 2011 (EST)
1. Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTR Mutation
Effect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTR Mutation
2. Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis
Abstract
Chronic Pseudomonas aeruginosa lung infection in cystic fibrosis (CF) patients is caused by biofilm-growing mucoid strains. Biofilms can be prevented by early aggressive antibiotic prophylaxis or therapy, and they can be treated by chronic suppressive therapy. New results from one small trial suggest that addition of oral ciprofloxacin to inhaled tobramycin may reduce lung inflammation. Clinical trials with new formulations of old antibiotics for inhalation therapy (aztreonam lysine) against chronic P. aeruginosa infection improved patient-reported outcome, lung function, time to acute exacerbations and sputum density of P. aeruginosa. Other drugs such as quinolones are currently under investigation for inhalation therapy. A trial of the use of anti-Pseudomonas antibiotics for long-term prophylaxis showed no effect in patients who were not already infected. Use of azithromycin to treat CF patients without P. aeruginosa infection did not improve lung function. Here I review the recent advances in the treatment of P. aeruginosa lung infections with a focus on inhalation treatments targeted at prophylaxis and chronic suppressive therapy. [3]
3. Changes in strategies for optimal antibacterial therapy in cystic fibrosis.
Abstract
Aggressive antibiotic therapy of bacterial airway infection is one of the main reasons for the dramatic increase in life expectancy over the last few decades. Staphylococcus aureus and Haemophilus influenzae are the predominant pathogens in younger patients, but the choice of antibiotic therapy against these pathogens remains highly controversial. There is general agreement that patients with pulmonary exacerbations should be treated and many cystic fibrosis (CF) centres will also try to eradicate bacteria in the absence of symptoms. Prophylactic antibiotic therapy, with anti-staphylococcal medications started at the time of diagnosis, is advocated by some groups but its positive effect remains unproven. In fact, recent studies have suggested that continuous prophylactic treatment with anti-staphylococcal antibiotics may increase the risk of early colonisation with Pseudomonas aeruginosa. P. aeruginosa is the main pathogen in older children with CF. While chronic airway infection with mucoid P. aeruginosa is considered irreversible, both the combination of oral ciprofloxacin with inhaled colistin and inhaled tobramycin alone has been used successfully in the early phase of colonisation. In patients chronically infected with P. aeruginosa, standard treatment of pulmonary exacerbations consists of intravenous combination therapy for 2-3 weeks. Controversy exists whether this treatment should be performed routinely every 3 months or only in the presence of a pulmonary exacerbation. Inhaled antibiotics such as tobramycin have been shown to improve lung function and reduce sputum density of P. aeruginosa, but both the optimal dose and the duration of therapy are unclear at the present time [4]
Review:
Inhaled bronchodilators for cystic fibrosis. Halfhide C, Evans HJ, Couriel J. Cochrane Database of Systematic Reviews 2005, Issue 4. Art. No.: CD003428. DOI: 10.1002/14651858.CD003428.pub2 from http://www2.cochrane.org/reviews/en/ab003428.html
Research Article: Identification of airborne dissemination of epidemic multiresistant strains of Pseudomonas aeruginosa at a CF centre during a cross infection outbreak. Jones AM, Govan JR, Doherty CJ, Dodd ME. Isalska BJ, Stanbridge TN, Webb AK. Thorax 58(6), 525-527. from http://www.ncbi.nlm.nih.gov/pubmed/12775867 --Rahul Mohan 10:58, 11 August 2011 (EST)
